John Greene bought $314k of CRSP
director at CRISPR Therapeutics AG. 7,000 shares at an average of $44.85, traded Feb 26, 2025, filed Feb 28, 2025.
Score components
- +15RoleDirector
- +14Trade size$314k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.8%, 3m -17.4%, 6m +18.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-030181, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 26, 2025 | POpen-market purchase Common Shares | +7,000 | $44.85 | $314k | 7,000 | Feb 28, 2025 |
Related signals
Other insiders at CRISPR Therapeutics AG and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $119k 1,990 shares | -2% | |
| 8Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $626k 10,400 shares | -10% | |
| 40Moderate | CRISPR Therapeutics AG | Ali Behbahani director | $781k 13,679 shares | -45% | |
| 17Weak | CRSPsell CRISPR Therapeutics AG | Naimish Patel Chief Medical Officer | $211k 3,786 shares | -16% | |
| 38Weak | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $173k 3,708 shares | -19% | |
| 42Moderate | CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $469k 10,020 shares | -4% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $149k 3,182 shares | -3% | |
| 43Moderate | CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $499k 10,349 shares | -4% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $166k 3,450 shares | -4% | |
| 50Moderate | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $476k 9,869 shares | -42% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.